Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of 212Pb-DOTAM-GRPR1 in Recurrent or Metastatic GRPR-expressing Tumors
NCT05283330Phase 1Recruiting
- Sponsor
- Orano Med
- Start
- Dec 2022
- Primary completion
- Jan 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ²¹²Pb-DOTAM-GRPR1 in Cervical Cancer (CC), breast cancer, colorectal cancer (CRC) and 3 more, sponsored by Orano Med. Primary endpoint: Recommended Phase 2 Dose at 14 months. Started Dec 2022; status: recruiting.
02
Drugs
²¹²Pb-DOTAM-GRPR1
03
Conditions
Cervical Cancer (CC)breast cancercolorectal cancer (CRC)non-small cell lung cancer (NSCLC)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05283330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05283330.